Resveratrol (trans-3,4’,5-trihydroxystilbene), a natural polyphenolic compound detected in grapes, berries, and
peanuts, possesses a wide spectrum of pharmacological properties, including anti-tumor metastasis activities. However,
the underlying mechanisms through which resveratrol inhibits the metastasis of pancreatic cancer are still not fully elucidated.
As epithelial-to-mesenchymal transition (EMT) is a key player for metastasis in tumor, the aim of this study is to
determine whether resveratrol affects EMT in pancreatic cancer cells and the related mechanism. The results showed that
resveratrol not only inhibited cell proliferation, migration, and invasion in a dose-dependent manner, but also mediated the
expression of EMT-related genes (E-cadherin, N-cadherin, vimentin, MMP-2, and MMP-9) which are important for cancer
cellular motility, invasiveness and metastasis during tumorigenesis. In addition, the levels of phospho-Akt and phospho-
NF-κB in BxPC-3 and Panc-1 cells were reduced by both resveratrol and LY294002 (a PI3-K inhibitor). Furthermore,
transforming growth factor-β (TGF-β)-induced alterations in cell morphology that are characteristic of EMT as well as increased
cell invasive ability could also be reversed by resveratrol. Taken together, these data indicate that resveratrol suppresses
pancreatic cancer migration and invasion through the inhibition of the PI-3K/Akt/NF-κB signaling pathway. This
study suggests that resveratrol may be a potential anticancer agent for pancreatic cancer.